Tarsus Pharmaceuticals, Inc. Overview
TARS market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 67.73
- H
- 68.87
- L
- 67.25
- C
- 68.72
- Vol
- 6,557.00
Daily history from Oct 16, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $67.73
- Previous Close
- $67.46
- Day High
- $68.87
- Day Low
- $67.25
- 52 Week High
- $91.44
- 52 Week Low
- $54.18
- 7 Day Return
- -8.28%
- 30 Day Return
- -6.53%
- 90 Day Return
- +1.54%
- 1 Year Return
- +1.01%
- Daily Notional Volume
- $450.6K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -7.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $53.89 – $91.53 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.3B · P/B 10.12 · P/S 5.49.